Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.
Conditions: Breast Cancer; Ovarian Cancer; Liposarcoma; Non-small Cell Lung Cancer (NSCLC); Endometrial; Solid Tumors Interventions: Drug: PF-07224826; Combination Product: Fulvestrant Sponsor: Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 15, 2023 Category: Research Source Type: clinical trials
A Behavioral Intervention to Promote Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia
Conditions: Endometrial Hyperplasia; Grade 1 Endometrial Cancer Interventions: Behavioral: Telemedicine behavioral weight intervention; Drug: Progestin; Behavioral: Enhanced usual care; Drug: Levonorgestrel-releasing IUD. Sponsor: Washington University School of Medicine Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 15, 2023 Category: Research Source Type: clinical trials
Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.
Conditions: Breast Cancer; Ovarian Cancer; Liposarcoma; Non-small Cell Lung Cancer (NSCLC); Endometrial; Solid Tumors Interventions: Drug: PF-07224826; Combination Product: Fulvestrant Sponsor: Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 15, 2023 Category: Research Source Type: clinical trials
A Behavioral Intervention to Promote Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia
Conditions: Endometrial Hyperplasia; Grade 1 Endometrial Cancer Interventions: Behavioral: Telemedicine behavioral weight intervention; Drug: Progestin; Behavioral: Enhanced usual care; Drug: Levonorgestrel-releasing IUD. Sponsor: Washington University School of Medicine Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 15, 2023 Category: Research Source Type: clinical trials
Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.
Conditions: Breast Cancer; Ovarian Cancer; Liposarcoma; Non-small Cell Lung Cancer (NSCLC); Endometrial; Solid Tumors Interventions: Drug: PF-07224826; Combination Product: Fulvestrant Sponsor: Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 15, 2023 Category: Research Source Type: clinical trials
A Behavioral Intervention to Promote Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia
Conditions: Endometrial Hyperplasia; Grade 1 Endometrial Cancer Interventions: Behavioral: Telemedicine behavioral weight intervention; Drug: Progestin; Behavioral: Enhanced usual care; Drug: Levonorgestrel-releasing IUD. Sponsor: Washington University School of Medicine Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 15, 2023 Category: Research Source Type: clinical trials
Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.
Conditions: Breast Cancer; Ovarian Cancer; Liposarcoma; Non-small Cell Lung Cancer (NSCLC); Endometrial; Solid Tumors Interventions: Drug: PF-07224826; Combination Product: Fulvestrant Sponsor: Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 15, 2023 Category: Research Source Type: clinical trials
A Behavioral Intervention to Promote Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia
Conditions: Endometrial Hyperplasia; Grade 1 Endometrial Cancer Interventions: Behavioral: Telemedicine behavioral weight intervention; Drug: Progestin; Behavioral: Enhanced usual care; Drug: Levonorgestrel-releasing IUD. Sponsor: Washington University School of Medicine Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 14, 2023 Category: Research Source Type: clinical trials
Study and Transformation of Tumor Molecular Features Screening Model of Endometrial Carcinoma Surgical Approach
Conditions: Endometrial Carcinoma; Tumor Molecular Features Screening Model Interventions: Procedure: open surgery; Procedure: laparoscopic surgery Sponsor: Peking University People's Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 8, 2023 Category: Research Source Type: clinical trials
